Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

BACKGROUND: Delayed-release dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile for patients with relapsing–remitting multiple sclerosis (RRMS) in phase 3 DEFINE/CONFIRM studies. ENDORSE is an ongoing long-term extension of DEFINE/CONFIRM. OBJECTIVE: We report e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Arnold, Douglas L, Bar-Or, Amit, Hutchinson, Michael, Kappos, Ludwig, Havrdova, Eva, MacManus, David G, Yousry, Tarek A, Pozzilli, Carlo, Selmaj, Krysztof, Sweetser, Marianne T, Zhang, Ray, Yang, Minhua, Potts, James, Novas, Mark, Miller, David H, Kurukulasuriya, Nuwan C, Fox, Robert J, Phillips, Theodore J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418934/
https://www.ncbi.nlm.nih.gov/pubmed/27207449
http://dx.doi.org/10.1177/1352458516649037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418934/
https://www.ncbi.nlm.nih.gov/pubmed/27207449
http://dx.doi.org/10.1177/1352458516649037

Ejemplares similares